Current Report Filing (8-k)
June 02 2015 - 5:12PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 27, 2015
MYRIAD GENETICS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware |
|
0-26642 |
|
87-0494517 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
320 Wakara Way
Salt Lake City, Utah 84108
(Address of principal executive offices) (Zip Code)
Registrants telephone number, including area code: (801) 584-3600
Not Applicable
(Former
name or former address, if changed since last report)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
ITEM 5.02(e) Compensatory Arrangements of Certain Officers.
On May 27, 2015 the Compensation Committee of the Board of Directors of Myriad Genetics, Inc. (the Committee) determined to award an annual
cash incentive bonus for FY 2015 to the executive officers set forth below under criteria set forth in Companys 2013 Executive Incentive Plan (the Plan). The Committee reviewed the performance criteria for the officers under the
Plan for the FY 2015 annual incentive bonus awards and determined to award the annual cash incentive bonus amounts for the officers FY 2015 annual cash incentive bonus award to be consistent with the level of annual incentive compensation
being awarded to employees under the Companys other annual incentive plans for the fiscal year. The award amounts are below the target bonus amounts for each officer. The award amounts were based on the level of financial performance of the
Company and the officers individual goals and accomplishments for the fiscal year. No other amount will be awarded to these officers for their annual cash incentive bonus for FY 2015.
|
|
|
|
|
|
|
|
|
Officer |
|
FY 2014 |
|
|
FY 2015 |
|
Peter D. Meldrum, President and CEO |
|
$ |
1,293,500 |
|
|
$ |
762,200 |
|
Mark C. Capone, President, MGL |
|
$ |
552,000 |
|
|
$ |
333,000 |
|
Jerry S. Lanchbury, Chief Scientific Officer |
|
$ |
282,000 |
|
|
$ |
173,900 |
|
Richard M. Marsh, EVP, General Counsel and Secretary |
|
$ |
276,000 |
|
|
$ |
173,900 |
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
MYRIAD GENETICS, INC. |
|
|
|
|
Date: June 2, 2015 |
|
|
|
By: |
|
/s/ Peter D. Meldrum |
|
|
|
|
|
|
Peter D. Meldrum |
|
|
|
|
|
|
President and Chief Executive Officer |
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Apr 2024 to May 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From May 2023 to May 2024